Skip to main content
SpringerLink
Log in

Salivary Gland Diseases, Hyposalivation, and Xerostomia in Head and Neck Cancer Patients

  • Chapter
  • First Online:
Orofacial Supportive Care in Cancer

Abstract

Treatment of head and neck cancers is associated with an increased risk for hyposalivation and xerostomia. Salivary glands are often unavoidable, indirect targets during radiation treatment and are damaged in a cumulative radiation dose-related fashion resulting in partial to total permanent loss of function of salivary gland tissue and patients experiencing xerostomia. Salivary gland hypofunction and xerostomia lead to negative impacts on patients’ oral environment, function, and quality of life. Treatment remedies have limited effectiveness and may be accompanied by high financial burdens. This chapter represents information regarding the prevalence, severity, and management strategies for salivary gland hypofunction and xerostomia induced by cancer therapies with particular focus on effects of radiation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Bibliography

  1. Deasy JO, Moiseenko V, Marks L, Chao KS, Nam J, Eisbruch A. Radiotherapy dose-volume effects on salivary gland function. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S58–63. https://doi.org/10.1016/j.ijrobp.2009.06.090.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Jensen SB, Pedersen AM, Vissink A, Andersen E, Brown CG, Davies AN, et al. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer. 2010;18(8):1039–60.

    Article  Google Scholar 

  3. Pedersen AM, Bardow A, Jensen SB, Nauntofte B. Saliva and gastrointestinal functions of taste, mastication, swallowing and digestion. Oral Dis. 2002;8(3):117–29.

    Article  Google Scholar 

  4. Dawes C, Ong BY. Circadian rhythms in the flow rate and proportional contribution of parotid to whole saliva volume in man. Arch Oral Biol. 1973;18(9):1145–53.

    Article  Google Scholar 

  5. Dawes C, Wood CM. The contribution of oral minor mucous gland secretions to the volume of whole saliva in man. Arch Oral Biol. 1973;18(3):337–42.

    Article  Google Scholar 

  6. Sreebny LM. Saliva in health and disease: an appraisal and update. Int Dent J. 2000;50(3):140–61.

    Article  Google Scholar 

  7. Dawes C. Physiological factors affecting salivary flow rate, oral sugar clearance, and the sensation of dry mouth in man. J Dent Res. 1987;66(Special Issue):648–53.

    Article  Google Scholar 

  8. Yeh SA, Huang YJ. Dose escalation for patients with locally advanced nasopharyngeal carcinoma treated with radiotherapy alone. Am J Clin Oncol. 2007;30(4):401–5. https://doi.org/10.1097/COC.0b013e31803377b3.

    Article  PubMed  Google Scholar 

  9. Franzen L, Funegard U, Ericson T, Henriksson R. Parotid gland function during and following radiotherapy of malignancies in the head and neck. A consecutive study of salivary flow and patient discomfort. Eur J Cancer. 1992;28(2–3):457–62.

    Article  Google Scholar 

  10. Jensen SB, Pedersen AM, Vissink A, Andersen E, Brown CG, Davies AN, et al. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact. Support Care Cancer. 2010;18(8):1061–79.

    Article  Google Scholar 

  11. Jeong SY, Kim HW, Lee SW, Ahn BC, Lee J. Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms. Thyroid. 2013;23(5):609–16. https://doi.org/10.1089/thy.2012.0106.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Soo Roh S, Wook Kim D, Jin Baek H. Association of xerostomia and ultrasonographic features of the major salivary glands after radioactive iodine ablation for papillary thyroid carcinoma. AJR Am J Roentgenol. 2016;207(5):1077–81. https://doi.org/10.2214/AJR.15.15776.

    Article  PubMed  Google Scholar 

  13. Laaksonen M, Ramseier AM, Rovo A, Jensen SB, Raber-Durlacher JE, Zitzmann NU, et al. Longitudinal assessment of hematopoietic stem cell transplantation and hyposalivation. J Dent Res. 2011;90(10):1177–82. https://doi.org/10.1177/0022034511414156.

    Article  PubMed  Google Scholar 

  14. Daikeler T, Mauramo M, Rovo A, Stern M, Halter J, Buser A, et al. Sicca symptoms and their impact on quality of life among very long-term survivors after hematopoietic SCT. Bone Marrow Transplant. 2013;48(7):988–93. https://doi.org/10.1038/bmt.2012.260.

    Article  PubMed  Google Scholar 

  15. Chao KS, Deasy JO, Markman J, Haynie J, Perez CA, Purdy JA, et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys. 2001;49(4):907–16. S0360-3016(00)01441-3 [pii].

    Article  Google Scholar 

  16. Eisbruch A, Ten Haken RK, Kim HM, Marsh LH, Ship JA. Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys. 1999;45(3):577–87.

    Article  Google Scholar 

  17. Blanco AI, Chao KS, El Naqa I, Franklin GE, Zakarian K, Vicic M, et al. Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62(4):1055–69. https://doi.org/10.1016/j.ijrobp.2004.12.076.

    Article  PubMed  Google Scholar 

  18. Saarilahti K, Kouri M, Collan J, Hamalainen T, Atula T, Joensuu H, et al. Intensity modulated radiotherapy for head and neck cancer: evidence for preserved salivary gland function. Radiother Oncol. 2005;74(3):251–8. https://doi.org/10.1016/j.radonc.2004.11.004.

    Article  PubMed  Google Scholar 

  19. Li Y, Taylor JM, Ten Haken RK, Eisbruch A. The impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2007;67(3):660–9. S0360-3016(06)02988-9 [pii]. https://doi.org/10.1016/j.ijrobp.2006.09.021.

    Article  PubMed  Google Scholar 

  20. Munter MW, Karger CP, Hoffner SG, Hof H, Thilmann C, Rudat V, et al. Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy. Int J Radiat Oncol Biol Phys. 2004;58(1):175–84.

    Article  Google Scholar 

  21. Liu WS, Lee SP, Lee JK, Su MC, Chen GD, Lee HS, et al. Factors influencing the parotid function in nasopharyngeal carcinoma treated with parotid-sparing radiotherapy. Jpn J Clin Oncol. 2006;36(10):626–31. https://doi.org/10.1093/jjco/hyl098.

    Article  PubMed  Google Scholar 

  22. Roesink JM, Moerland MA, Battermann JJ, Hordijk GJ, Terhaard CH. Quantitative dose-volume response analysis of changes in parotid gland function after radiotherapy in the head-and-neck region. Int J Radiat Oncol Biol Phys. 2001;51(4):938–46.

    Article  Google Scholar 

  23. Scrimger R. Salivary gland sparing in the treatment of head and neck cancer. Expert Rev Anticancer Ther. 2011;11(9):1437–48. https://doi.org/10.1586/era.11.101.

    Article  PubMed  Google Scholar 

  24. Chao KS, Majhail N, Huang CJ, Simpson JR, Perez CA, Haughey B, et al. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiother Oncol. 2001;61(3):275–80.

    Article  Google Scholar 

  25. Wang ZH, Yan C, Zhang ZY, Zhang CP, Hu HS, Tu WY, et al. Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study. Int J Radiat Oncol Biol Phys. 2011;81(5):1479–87. https://doi.org/10.1016/j.ijrobp.2010.07.1990.

    Article  PubMed  Google Scholar 

  26. Saarilahti K, Kouri M, Collan J, Kangasmaki A, Atula T, Joensuu H, et al. Sparing of the submandibular glands by intensity modulated radiotherapy in the treatment of head and neck cancer. Radiother Oncol. 2006;78(3):270–5. https://doi.org/10.1016/j.radonc.2006.02.017.

    Article  PubMed  Google Scholar 

  27. Lalla RV, Treister N, Sollecito T, Schmidt B, Patton LL, Mohammadi K, et al. Oral complications at 6 months after radiation therapy for head and neck cancer. Oral Dis. 2017; https://doi.org/10.1111/odi.12710.

  28. Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000;18(19):3339–45.

    Article  Google Scholar 

  29. Wasserman TH, Brizel DM, Henke M, Monnier A, Eschwege F, Sauer R, et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and-neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. Int J Radiat Oncol Biol Phys. 2005;63(4):985–90. https://doi.org/10.1016/j.ijrobp.2005.07.966.

    Article  PubMed  Google Scholar 

  30. Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol. 2009;27(1):127–45. https://doi.org/10.1200/JCO.2008.17.2627.

    Article  PubMed  Google Scholar 

  31. Brizel DM, Overgaard J. Does amifostine have a role in chemoradiation treatment? Lancet Oncol. 2003;4(6):378–81.

    Article  Google Scholar 

  32. Riley P, Glenny AM, Hua F, Worthington HV. Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy. Cochrane Database Syst Rev. 2017;7:CD012744. https://doi.org/10.1002/14651858.CD012744.

    Article  PubMed  Google Scholar 

  33. Takahashi I, Nagai T, Miyaishi K, Maehara Y, Niibe H. Clinical study of the radioprotective effects of Amifostine (YM-08310, WR-2721) on chronic radiation injury. Int J Radiat Oncol Biol Phys. 1986;12(6):935–8.

    Article  Google Scholar 

  34. Ozsahin M, Betz M, Matzinger O, Bron L, Luthi F, Pasche P, et al. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy. Arch Otolaryngol Head Neck Surg. 2006;132(2):141–5. https://doi.org/10.1001/archotol.132.2.141.

    Article  PubMed  Google Scholar 

  35. Law A, Kennedy T, Pellitteri P, Wood C, Christie D, Yumen O. Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2007;69(5):1361–8. https://doi.org/10.1016/j.ijrobp.2007.05.052.

    Article  PubMed  Google Scholar 

  36. Chambers MS, Posner M, Jones CU, Biel MA, Hodge KM, Vitti R, et al. Cevimeline for the treatment of postirradiation xerostomia in patients with head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;68(4):1102–9. S0360-3016(07)00149-6 [pii]. https://doi.org/10.1016/j.ijrobp.2007.01.019.

    Article  PubMed  Google Scholar 

  37. Chambers MS, Jones CU, Biel MA, Weber RS, Hodge KM, Chen Y, et al. Open-label, long-term safety study of cevimeline in the treatment of postirradiation xerostomia. Int J Radiat Oncol Biol Phys. 2007;69(5):1369–76. https://doi.org/10.1016/j.ijrobp.2007.05.024.

    Article  PubMed  Google Scholar 

  38. Jham BC, Teixeira IV, Aboud CG, Carvalho AL, Coelho Mde M, Freire AR. A randomized phase III prospective trial of bethanechol to prevent radiotherapy-induced salivary gland damage in patients with head and neck cancer. Oral Oncol. 2007;43(2):137–42. https://doi.org/10.1016/j.oraloncology.2006.01.013.

    Article  PubMed  Google Scholar 

  39. Mercadante V, Al Hamad A, Lodi G, Porter S, Fedele S. Interventions for the management of radiotherapy-induced xerostomia and hyposalivation: a systematic review and meta-analysis. Oral Oncol. 2017;66:64–74. https://doi.org/10.1016/j.oraloncology.2016.12.031.

    Article  PubMed  Google Scholar 

  40. Wiseman LR, Faulds D. Oral pilocarpine: a review of its pharmacological properties and clinical potential in xerostomia. Drugs. 1995;49(1):143–56.

    Article  Google Scholar 

  41. Fox PC, Atkinson JC, Macynski AA, Wolff A, Kung DS, Valdez IH, et al. Pilocarpine treatment of salivary gland hypofunction and dry mouth (xerostomia). Arch Intern Med. 1991;151(6):1149–52.

    Article  Google Scholar 

  42. Johnson JT, Ferretti GA, Nethery WJ, Valdez IH, Fox PC, Ng D, et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med. 1993;329(6):390–5.

    Article  Google Scholar 

  43. LeVeque FG, Montgomery M, Potter D, Zimmer MB, Rieke JW, Steiger BW, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. J Clin Oncol. 1993;11(6):1124–31.

    Article  Google Scholar 

  44. Davies AN, Singer J. A comparison of artificial saliva and pilocarpine in radiation-induced xerostomia. J Laryngol Otol. 1994;108(8):663–5.

    Article  Google Scholar 

  45. Hamlar DD, Schuller DE, Gahbauer RA, Buerki RA, Staubus AE, Hall J, et al. Determination of the efficacy of topical oral pilocarpine for postirradiation xerostomia in patients with head and neck carcinoma. Laryngoscope. 1996;106(8):972–6.

    Article  Google Scholar 

  46. Taweechaisupapong S, Pesee M, Aromdee C, Laopaiboon M, Khunkitti W. Efficacy of pilocarpine lozenge for post-radiation xerostomia in patients with head and neck cancer. Aust Dent J. 2006;51(4):333–7.

    Article  Google Scholar 

  47. Bernardi R, Perin C, Becker FL, Ramos GZ, Gheno GZ, Lopes LR, et al. Effect of pilocarpine mouthwash on salivary flow. Braz J Med Biol Res. 2002;35(1):105–10.

    Article  Google Scholar 

  48. Daniels TE, Wu AJ. Xerostomia—clinical evaluation and treatment in general practice. J Calif Dent Assoc. 2000;28(12):933–41.

    PubMed  Google Scholar 

  49. Senahayake F, Piggott K, Hamilton-Miller JM. A pilot study of Salix SST (saliva-stimulating lozenges) in post-irradiation xerostomia. Curr Med Res Opin. 1998;14(3):155–9. https://doi.org/10.1185/03007999809113355.

    Article  PubMed  Google Scholar 

  50. Jensdottir T, Nauntofte B, Buchwald C, Hansen HS, Bardow A. Effects of sucking acidic candies on saliva in unilaterally irradiated pharyngeal cancer patients. Oral Oncol. 2006;42(3):317–22. https://doi.org/10.1016/j.oraloncology.2005.08.009.

    Article  PubMed  Google Scholar 

  51. S-Gravenmade EJ, Roukema PA, Panders AK. The effect of mucin-containing artificial saliva on severe xerostomia. Int J Oral Surg. 1974;3(6):435–9.

    Article  Google Scholar 

  52. Regelink G, Vissink A, Reintsema H, Nauta JM. Efficacy of a synthetic polymer saliva substitute in reducing oral complaints of patients suffering from irradiation-induced xerostomia. Quintessence Int. 1998;29(6):383–8.

    PubMed  Google Scholar 

  53. Epstein JB, Stevenson-Moore P. A clinical comparative trial of saliva substitutes in radiation-induced salivary gland hypofunction. Spec Care Dentist. 1992;12(1):21–3.

    Article  Google Scholar 

  54. Furness S, Worthington HV, Bryan G, Birchenough S, McMillan R. Interventions for the management of dry mouth: topical therapies. Cochrane Database Syst Rev. 2011;12:CD008934. https://doi.org/10.1002/14651858.CD008934.pub2.

    Article  Google Scholar 

  55. Scrimger RA, Seikaly H, Vos LJ, Harris J, O’Connell D, Ghosh S, et al. Combination of submandibular salivary gland transfer and intensity-modulated radiotherapy to reduce dryness of mouth (xerostomia) in patients with head and neck cancer. Head Neck. 2018; https://doi.org/10.1002/hed.25339.

  56. Jha N, Seikaly H, Harris J, Williams D, Liu R, McGaw T, et al. Prevention of radiation induced xerostomia by surgical transfer of submandibular salivary gland into the submental space. Radiother Oncol. 2003;66(3):283–9.

    Article  Google Scholar 

  57. Pathak KA, Bhalavat RL, Mistry RC, Deshpande MS, Bhalla V, Desai SB, et al. Upfront submandibular salivary gland transfer in pharyngeal cancers. Oral Oncol. 2004;40(9):960–3. https://doi.org/10.1016/j.oraloncology.2004.04.016.

    Article  PubMed  Google Scholar 

  58. Seikaly H, Jha N, Harris JR, Barnaby P, Liu R, Williams D, et al. Long-term outcomes of submandibular gland transfer for prevention of postradiation xerostomia. Arch Otolaryngol Head Neck Surg. 2004;130(8):956–61. https://doi.org/10.1001/archotol.130.8.956.

    Article  PubMed  Google Scholar 

  59. Al-Qahtani K, Hier MP, Sultanum K, Black MJ. The role of submandibular salivary gland transfer in preventing xerostomia in the chemoradiotherapy patient. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101(6):753–6. https://doi.org/10.1016/j.tripleo.2005.12.017.

    Article  PubMed  Google Scholar 

  60. Johnstone PA, Peng YP, May BC, Inouye WS, Niemtzow RC. Acupuncture for pilocarpine-resistant xerostomia following radiotherapy for head and neck malignancies. Int J Radiat Oncol Biol Phys. 2001;50(2):353–7.

    Article  Google Scholar 

  61. Blom M, Dawidson I, Fernberg JO, Johnson G, Angmar-Mansson B. Acupuncture treatment of patients with radiation-induced xerostomia. Eur J Cancer B Oral Oncol. 1996;32B(3):182–90.

    Article  Google Scholar 

  62. Blom M, Lundeberg T. Long-term follow-up of patients treated with acupuncture for xerostomia and the influence of additional treatment. Oral Dis. 2000;6(1):15–24.

    Article  Google Scholar 

  63. Cho JH, Chung WK, Kang W, Choi SM, Cho CK, Son CG. Manual acupuncture improved quality of life in cancer patients with radiation-induced xerostomia. J Altern Complement Med. 2008;14(5):523–6. https://doi.org/10.1089/acm.2007.0793.

    Article  PubMed  Google Scholar 

  64. Zhuang L, Yang Z, Zeng X, Zhua X, Chen Z, Liu L, et al. The preventive and therapeutic effect of acupuncture for radiation-induced xerostomia in patients with head and neck cancer: a systematic review. Integr Cancer Ther. 2013;12(3):197–205. https://doi.org/10.1177/1534735412451321.

    Article  PubMed  Google Scholar 

  65. Forner L, Hyldegaard O, von Brockdorff AS, Specht L, Andersen E, Jansen EC, et al. Does hyperbaric oxygen treatment have the potential to increase salivary flow rate and reduce xerostomia in previously irradiated head and neck cancer patients? A pilot study. Oral Oncol. 2011;47(6):546–51. https://doi.org/10.1016/j.oraloncology.2011.03.021.

    Article  PubMed  Google Scholar 

  66. Gerlach NL, Barkhuysen R, Kaanders JH, Janssens GO, Sterk W, Merkx MA. The effect of hyperbaric oxygen therapy on quality of life in oral and oropharyngeal cancer patients treated with radiotherapy. Int J Oral Maxillofac Surg. 2008;37(3):255–9. https://doi.org/10.1016/j.ijom.2007.11.013.

    Article  PubMed  Google Scholar 

  67. Harding SA, Hodder SC, Courtney DJ, Bryson PJ. Impact of perioperative hyperbaric oxygen therapy on the quality of life of maxillofacial patients who undergo surgery in irradiated fields. Int J Oral Maxillofac Surg. 2008;37(7):617–24. https://doi.org/10.1016/j.ijom.2008.04.004.

    Article  PubMed  Google Scholar 

  68. Sasportas LS, Hosford DN, Sodini MA, Waters DJ, Zambricki EA, Barral JK, et al. Cost-effectiveness landscape analysis of treatments addressing xerostomia in patients receiving head and neck radiation therapy. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;116(1):e37–51. https://doi.org/10.1016/j.oooo.2013.02.017.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oral Medicine, Atrium Health’s Carolinas Medical Center, Charlotte, NC, USA

    Jillian Rigert & Michael T. Brennan

Authors
  1. Jillian Rigert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael T. Brennan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael T. Brennan .

Editor information

Editors and Affiliations

  1. Oral Medicine and Oral Oncology, Griffith University, QLD, Australia

    Raj Nair

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Rigert, J., Brennan, M.T. (2022). Salivary Gland Diseases, Hyposalivation, and Xerostomia in Head and Neck Cancer Patients. In: Nair, R. (eds) Orofacial Supportive Care in Cancer . Springer, Cham. https://doi.org/10.1007/978-3-030-86510-8_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-86510-8_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-86509-2

  • Online ISBN: 978-3-030-86510-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation